Skip to main content
TipRanks
Go Ultimate75% OFF

Lifecore Biomedical (LFCR) AI Stock Analysis

154 Followers
LFCR

Lifecore Biomedical

(NASDAQ:LFCR)

Select Model
Rating:52Neutral
Price Target:$6.50â–²(1.25% Upside)
Action:reiterated
Date:11/05/26

The score is held down primarily by weak financial performance—ongoing losses and a strained balance sheet with negative equity—despite improved 2026 cash flow. Technicals add support with the price above key moving averages and positive momentum. Corporate events (take-private deal progress and the long-term Alcon agreement) provide meaningful near-term support, while valuation remains hard to justify on earnings given the negative P/E.

Positive Factors
Long-term customer visibilityThe Alcon extension provides a multi-year framework for purchase volumes and supply commitments, improving revenue visibility beyond the next few quarters. Automatic renewals and a deeper strategic relationship can support capacity planning and make a portion of Lifecore’s CDMO demand more durable.
Negative Factors
Persistent unprofitabilityRevenue contraction combined with operating and net losses shows that Lifecore has not yet translated its CDMO activity into dependable earnings. The reversal from positive net income in 2024 to sizable losses in 2025–2026 highlights earnings volatility and limits internally funded growth.

Lifecore Biomedical (LFCR) vs. SPDR S&P 500 ETF (SPY)

-60%-50%-40%-30%-20%-10%0%10%20%LFCR-15.53%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$243.36M
Dividend Yield
―
Average Volume (3M)
403.05K
Price to Earnings (P/E)
-3.4
Beta (1Y)
1.77
Revenue Growth
―
EPS Growth
―
Country
US
Employees
382
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Lifecore Biomedical Business Overview & Revenue Model

Company Description

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services i...

How the Company Makes Money

Lifecore primarily makes money by providing fee-for-service CDMO work to biopharmaceutical and biotechnology customers. Its core revenue stream is manufacturing services for injectable drug products, particularly sterile fill-finish, where customers...

Lifecore Biomedical Earnings Call Summary

Earnings Call Date:Mar 16, 2026(Q2-2026)|% Change Since:-1.83%|Next Earnings Date:Oct 03, 2023
Earnings Call SentimentNeutral

Balanced/Neutral. The call highlighted substantial strategic and operational progress — a growing late-stage pipeline, meaningful new business momentum (13 wins in 12 months), successful regulatory audits (including PMDA), sustained SG&A reductions (cumulative $16.2M) and improved liquidity ($38.8M) — and management reaffirmed 2026 guidance. However, near-term financials showed meaningful declines: Q2 revenue down 6.2% YoY and six-month revenue down 19.9%, widened net losses (Q2 and 6-month), and a sizable drop in 6-month adjusted EBITDA (~34.5%). Management expects a back-half recovery and a 2027–2028 volume inflection with a major customer's committed demand ramp, but execution and timing risks remain. Overall, positives around pipeline, wins, quality and cost discipline are offset by short-term revenue and profitability headwinds, yielding a neutral outlook.

Positive Updates

Guidance Reaffirmed for 2026
Company reaffirmed 2026 revenue guidance of $120.0M–$125.0M and adjusted EBITDA guidance of $20.5M–$25.0M, and reiterated expectation to deliver full-year guidance despite H1 timing headwinds.

Negative Updates

Revenue Declines — Q2 and 6-Month Results
Q2 2026 revenue of $34.2M declined $2.3M or 6.2% versus the comparable prior period; 6-month revenue of $57.4M declined $14.2M or 19.9% versus the comparable prior period, driven by timing, mix, lower development revenue and a prior-period contractual take-or-pay benefit.

Company Guidance

Lifecore reaffirmed 2026 guidance of $120–125 million in revenue and $20.5–25.0 million in adjusted EBITDA, noting H2 midpoint expectations of roughly $65 million in revenue and $13 million in adjusted EBITDA with a Q4-weighted back half and a step-up in CDMO/aseptic revenue; Q2 results were $34.2M revenue, $12.1M gross profit, $8.0M SG&A, $8.6M adjusted EBITDA and a $6.2M net loss ($0.19/share), while the six‑month totals were $57.4M revenue, $16.5M gross profit, $15.9M SG&A, $9.6M adjusted EBITDA and a $21.1M net loss ($0.61/share). Liquidity at quarter end was ~$38.8M (cash $17.2M + revolver availability $21.6M), free cash flow for the year is targeted at ~$7–10M, and the company has achieved cumulative SG&A/R&D savings of $16.2M since late‑2024 with SG&A expected to trend to about $6M/quarter (ex‑one‑time items) in the back half. Looking to the mid/long term, Lifecore reiterated a 12% revenue CAGR to 2029, a >25% adjusted EBITDA margin target by 2029, ~60% installed capacity utilization by 2029, and specific program/demand metrics including a doubling of committed fill/finish demand beginning in 2027 (and >200% increase in 2028 vs 2026), 11 development programs potentially commercializing by end‑2028, and recent business development wins (6 in Q2, 9 YTD, 13 LTM) with >60% of competed opportunities being late‑stage or site transfers.

Lifecore Biomedical Financial Statement Overview

Summary

Financials are stressed overall: revenue is roughly flat to down and profitability is weak with persistent losses (2026 EBIT margin ~-1.0% and net margin ~-23.8%). The balance sheet is a major risk with high leverage and negative equity in 2026, limiting flexibility. Cash flow is the main bright spot with positive 2026 operating cash flow (~$12.6M) and free cash flow (~$6.2M), but the historical trend is inconsistent.

Income Statement

34Negative

Balance Sheet

22Negative

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMDec 2025May 2025May 2024Aug 2023May 2022
Income Statement
Total Revenue91.53M129.46M128.87M128.26M103.27M111.27M
Gross Profit28.61M40.61M40.30M41.85M27.98M39.07M
EBITDA2.99M5.98M-8.81M35.56M-33.17M12.84M
Net Income-27.29M-30.79M-38.72M12.01M-99.56M-116.72M
Balance Sheet
Total Assets232.18M232.18M239.34M253.96M253.54M274.70M
Cash, Cash Equivalents and Short-Term Investments17.47M17.47M8.27M8.46M19.09M991.00K
Total Debt142.61M142.61M130.82M133.57M112.62M247.78M
Total Liabilities246.38M246.38M238.01M242.65M257.77M186.88M
Stockholders Equity-14.20M-14.20M1.34M11.31M-4.23M87.82M
Cash Flow
Free Cash Flow-106.28K6.23M-13.62M-18.14M-38.92M-52.53M
Operating Cash Flow3.05M12.57M-206.00K257.00K-17.44M-22.59M
Investing Cash Flow13.99M-1.63M-6.42M-18.39M-4.81M79.96M
Financing Cash Flow-6.52M-1.11M6.42M7.51M39.70M-57.02M

Lifecore Biomedical Technical Analysis

Technical Analysis SentimentPositive
Last Price6.42

Price Trends

50DMA5.79Positive
100DMA5.23Positive
200DMA5.41Positive

Market Momentum

MACD0.12Positive
RSI63.79Neutral
STOCH52.44Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Positive. The current price of 6.42 is above the 20-day moving average (MA) of 6.41, above the 50-day MA of 5.79, and above the 200-day MA of 5.41, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 63.79 is Neutral, neither overbought nor oversold. The STOCH value of 52.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFCR.

Lifecore Biomedical Risk Analysis

Lifecore Biomedical disclosed 30 risk factors in its most recent earnings report. Lifecore Biomedical reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our stockholders will experience significant dilution as a result of the issuance of shares of our Common Stock upon conversion of the Redeemable Convertible Preferred Stock.Q2, 2025
2.Future resales, or the perception of future resales, of our Common Stock may cause the market price of our Common Stock to drop significantly, even if our business is doing well.Q2, 2025
3.We have a history of losses. We may need additional capital and any additional capital we seek may not be available in the amount we need, at the time we need it or on terms favorable to us.Q2, 2025

Lifecore Biomedical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

LFCR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IRWDIRWD72Outperform$799.61M5.33-93.40%―18.09%403.76%
CPIXCPIX53Neutral$88.10M1.28202.58%23.57%-39.11%-241.27%
LFCRLFCR52Neutral$243.36M-3.40381.59%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
DERMDERM50Neutral$122.21M-23.29-16.07%―17.03%49.40%
BIOABIOA41Neutral$255.07M-2.18-31.42%―45.33%-20.81%

* Healthcare Sector Average

Performance Comparison

0%200%400%LFCRIRWDCPIXSXTCDERMBIOADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
LFCR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
LFCRLifecore Biomedical, Inc.6.42-1.48-18.73%
IRWDIronwood Pharmaceuticals4.831.7054.31%
CPIXCumberland Pharmaceuticals Inc.5.884.41299.19%
SXTCChina Sxt Pharmaceuticals3.00-1619997.00-100.00%
DERMJourney Medical Corporation4.33-3.36-43.69%
BIOABioAge Labs, Inc.5.55-2.76-33.21%

Lifecore Biomedical Corporate Events

M&A TransactionsRegulatory Filings and Compliance

Lifecore Biomedical Receives Antitrust Clearance for Proposed Merger

Positive
Nov 5, 2026

On September 27, 2026, Lifecore Biomedical entered into an agreement with Lifecore Inc. and Hazel Merger Sub to merge Hazel Merger Sub with and into the company, with Lifecore Biomedical surviving as a wholly owned subsidiary of Lifecore Inc. On Nove...

M&A TransactionsRegulatory Filings and ComplianceShareholder Meetings

Lifecore Sets Record Date for Merger Vote

Neutral
Oct 20, 2026

On September 27, 2026, Lifecore Biomedical, Inc. entered into a Merger Agreement with Lifecore Inc. and Hazel Merger Sub, Inc., and on October 16, 2026, its board set November 4, 2026, as the record date for a special stockholder meeting to vote on a...

Business Operations and Strategy

Lifecore Biomedical Extends Key Manufacturing Pact with Alcon

Positive
Sep 29, 2026

On September 24, 2026, Lifecore Biomedical entered into a Third Amendment to its Amended and Restated Contract Manufacturing Agreement with Alcon Research, effective November 1, 2026, extending the agreement’s initial term from December 31, 2031 to D...

Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing

Lifecore Biomedical to Go Private in Webster Buyout

Positive
Sep 28, 2026

On September 27–28, 2026, Lifecore Biomedical agreed to be acquired by an affiliate of private equity firm Webster Equity Partners in a deal valued at up to $663.7 million, assuming full achievement of performance milestones. The transaction, unanimo...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026